Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 321, Issue 1, pp 63–69 | Cite as

Hemodynamic alterations produced by N,N-di-n-propyldopamine in anesthetized dogs

  • Richard A. Hahn
  • Brian R. MacDonald


Intravenous infusion of N,N-di-n-propyldopamine (DPDA) (100–900 μg/kg) produced dose-related arterial hypotension which was accompanied by bradycardia at higher doses. Increments in arterial blood pressure induced by carotid artery occlusion were attenuated during administration of DPDA (600 μg/kg, i.v.), whereas cardiovascular compensation to postural change remained unaltered. DPDA-induced hypotension and its attenuation of carotid occlusion responses were prevented by pretreatment with sulpiride (0.5 mg/kg, i.v.), indicating involvement of dopamine receptors in these activities.

Hemodynamic studies demonstrated that DPDA (600 μg/kg, i.v.) lowered mean arterial blood pressure by dilating the systemic vasculature; mean aortic blood flow increased in the presence of bradycardia due to an increment in stroke volume. Left ventricular minute work, stroke work and myocardial oxygen consumption were decreased as a consequence of the hypotension and bradycardia produced by DPDA. The results of other experiments illustrated that propranolol (0.5 mg/kg, i.v.) and nitroglycerin (40 μg/kg, i.v.) administered in combination, but not individually, resulted in hemodynamic alterations similar to those of DPDA (600 μg/kg, i.v.). However, at equivalent reductions in mean arterial blood pressure, cardiac rate and myocardial oxygen consumption only DPDA increased mean aortic blood flow and lowered left ventricular end-diastolic pressure.

The hemodynamic effects produced by DPDA are interpreted to be a reflection of its known ability to inhibit neurogenic release of noradrenaline by stimulation of neuronal dopamine receptors. The composite data suggest that orally effective dopamine receptor agonists may have clinical utility as antihypertensive agents with minimal liability for producing orthostasis. Furthermore, a potential use in ischemic heart disease is suggested by data indicating that DPDA maintained systemic perfusion at reduced levels of myocardial work and oxygen consumption.

Key words

N,N-di-n-propyldopamine Dopamine receptors Hypotension Bradycardia Propranolol Nitroglycerin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amsterdam EA, Hughes JL, De Maria AN, Zelis R, Mason DT (1974) Indirect assessment of myocardial oxygen consumption in the evaluation of mechanisms and therapy of angina pectoris. Am J Cardiol 33:737–743Google Scholar
  2. Antonaccio MJ, Robson RD, Povalski HS (1973) Modification by antihypertensive drugs of reflex circulatory responses induced by vertical tilting or bilateral carotid occlusion. Eur J Pharmacol 22:23–31Google Scholar
  3. Baum T, Sabin D, Moran RM (1981) Comparison of hypotensive, orthostatic and sympathetic inhibitory actions of antihypertensive drugs in rats. Clin Exp Hypertension 3:219–243Google Scholar
  4. Bogaert MG, DeSchaepdryver AF, Willems JL (1977) Dopamine-induced neurogenic vasodilatation in the intact hindlimb of the dog. Br J Pharmacol 59:283–292Google Scholar
  5. Borowski E, Starke K, Ehrl H, Endo T (1977) A comparison of pre- and postsynaptic effects of α-adrenolytic drugs in the pulmonary artery of the rabbit. Neuroscience 2:285–296Google Scholar
  6. Braunwald E (1971) Control of myocardial oxygen consumption: Physiologic and clinical considerations. Am J Cardiol 27:416–432Google Scholar
  7. Clark BJ (1981) Dopamine receptors and the cardiovascular system. Postgrad Med J 57 (Suppl 1):45–54Google Scholar
  8. Constantine JW, McShane WK, Wang SC (1971) Comparison of carotid artery occlusion and tilt responses in dogs. Am J Physiol 221:1681–1685Google Scholar
  9. Corrodi H, Fuxe K, Hofkelt J, Lidbrink P, Ungerstedt U (1973) Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25:409–412Google Scholar
  10. Doxey JC, Smith CFC, Walker JM (1977) Selectivity of blocking agents for pre- and postsynaptic α-adrenoceptors. Br J Pharmacol 60:91–96Google Scholar
  11. Dray A, Oakley NR (1976) Bromocriptine and dopamine receptor stimulation. J Pharm Pharmacol 28:586–588Google Scholar
  12. Dubocovich ML, Langer SZ, Massingham R (1980) Inhibition of noradrenergic neurotransmission by dipropyldopamine through activation of presynaptic dopamine receptors. Br J Pharmacol 69:297–298PGoogle Scholar
  13. Fennell WH, Kohli JD, Goldberg LI (1980a) Hypotensive effects of N, N-Di-n-propyldopamine in the anesthetized dog: Comparison with sodium nitroprusside. J Cardiovasc Pharmacol 2:247–255Google Scholar
  14. Fennell WH, Taylor AA, Young JB, Farmer JA, Ginos J, Mitchell RR (1980b) Activation of presynaptic dopamine receptors in man: A new mechanism for afterload reduction. Clin Res 28:878AGoogle Scholar
  15. Gibson A, Samini M (1979) Interaction of dopamine agonists with peripheral alpha-adrenoceptors. In: Usdin E, Kopin IJ, Barchas JD (eds) Catecholamines: Basic and clinical frontiers, I. Pergamon Press, New York, p 417Google Scholar
  16. Goldberg LI, Volkman PH, Kohli JD (1978) A comparison of the vascular dopamine receptor with other dopamine receptors. Ann Rev Pharmacol Toxicol 18:57–79Google Scholar
  17. Greenacre JK, Teychenne PF, Petrie A, Calne DB, Leigh PN, Reid JL (1976) The cardiovascular effects of bromocriptine in parkinsonism. Br J Clin Pharmacol 3:571–574Google Scholar
  18. Hahn RA (1981) Inhibitory effects of pergolide on peripheral adrenergic neurotransmission in spontaneously hypertensive rats. Life Sci 29:2501–2509Google Scholar
  19. Hahn RA, Wardell JR (1980a) Antagonism of the renal vasodilator activity of dopamine by metoclopramide. Naunyn-Schmiedeberg's Arch Pharmacol 314:177–182Google Scholar
  20. Hahn RA, Wardell JR (1980b) Renal vascular activity of SK and F 38393 and dopamine in anesthetized dogs. J Cardiovasc Pharmacol 2:583–593Google Scholar
  21. Hahn RA, Farrell SK (1981) Inhibition of peripheral adrenergic neurotransmission by lergotrile in spontaneously hypertensive rats. Life Sci 28:2497–2504Google Scholar
  22. Kohli JD, Goldberg LI, Volkman PH, Cannon JG (1978) N,N-Di-n-propyldopamine: A qualitatively different dopamine vascular agonist. J Pharmacol Exp Ther 207:16–22Google Scholar
  23. Kohli JD, Listinsky JJ, Goldberg LI (1979) The inhibitory neurogenic effects of N,N-Di-n-propyldopamine: A vascular dopamine agonist. In: Imbs J, Schwartz J (eds) Peripheral dopaminergic receptors. Pergamon Press, New York, pp 249–255Google Scholar
  24. Langer SZ, Dubocovich ML (1979) Physiological and pharmacological role of the regulation of noradrenaline release by presynaptic dopamine receptors in the peripheral nervous system. In: Imbs J, Schwartz J (eds) Peripheral dopaminergic receptors. Pergamon Press, New York, pp 233–245Google Scholar
  25. Langer SZ, Cavero I, Massingham R (1980) Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 2:372–382Google Scholar
  26. Lefevre-Borg F, Cavero I (1980) Stimulation of peripheral dopamine receptors: A mechanism for novel antihypertensive agents. Clin Sci 59:291s-294sGoogle Scholar
  27. Lokhandwala MF, Tadepalli AS, Jandhyala BS (1979) Cardiovascular actions of bromocriptine: Evidence for a neurogenic mechanism. J Pharmacol Exp Ther 211:620–625Google Scholar
  28. Massingham R, Dubocovich ML, Langer SZ (1980) The role of presynaptic receptors in the cardiovascular actions of N,N-di-n-propyldopamine in the cat and dog. Naunyn-Schmiedeberg's Arch Pharmacol 314:17–28Google Scholar
  29. Parratt JR (1975) Recent advances in the pathophysiology and pharmacology of angina. Gen Pharmacol 6:247–251Google Scholar
  30. Snedecor GW (1956) Statistical Methods. Iowa State College Press, AmesGoogle Scholar
  31. Starke K, Borowski E, Endo T (1975) Preferential blockade of presynaptic α-adrenoceptors by yohimbine. Eur J Pharmacol 34:385–388Google Scholar
  32. Stumpe KO, Higuchi M, Kollock R, Kruck F, Vetter H (1977) Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Lancet 2:211–214Google Scholar
  33. Teychenne PF, Calne DB, Leigh PN, Greenacre JK, Reid JL, Bamji AN, Petrie A (1975) Idiopathic parkinsonism treated with bromocriptine. Lancet 2:473–476Google Scholar
  34. VanLoon GR, Sole MJ, Bain J, Ruse JL (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28:425–434Google Scholar
  35. Weitzell R, Tanaka T, Starke K (1979) Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 308:127–136Google Scholar
  36. Willems JL, Bogaert MG (1975) Dopamine-induced neurogenic vasodilatation in isolated perfused muscle preparation of the dog. Naunyn-Schmiedeberg's Arch Pharmacol 286:413–428Google Scholar
  37. Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O (1979) Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 25:137–142Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • Richard A. Hahn
    • 1
  • Brian R. MacDonald
    • 1
  1. 1.Department of Cardiovascular Pharmacology, The Lilly Research Laboratories, Mc-304Eli Lilly and CompanyIndianapolisUSA

Personalised recommendations